|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* Viral Neuroimmunology, Institut Pasteur, Paris, and
Centre d'Immunologie de Marseille-Luminy, Marseille, France;
Department of Neurology, Julius-Maximilians-University of Wuerzburg, Wuerzburg, Germany;
Instituto de Virologia, Universitad El Bosque, Bogota, Colombia;
¶ Department of Dermatology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21201; and
|| Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06510
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
T cell activation generally incorporates self-limiting mechanisms, such as inhibitory stimulation, to regulate T cell tolerance and attenuate the immune response. PD-1 (programmed death 1) is one member of the inhibitory molecules belonging to the B7-CD28 that provide inhibitory functions to B and T cells. PD-1 expressed on T and B cells has two ligands, B7-H1 (alternatively programmed cell death ligand 1, PD-L1) and B7-DC (alternatively programmed cell death ligand 2, PD-L2). Ligation of PD-1 by B7-H1 inhibits T cell proliferation and cytokine production, leading to immunological tolerance in different immune compartments (8, 9, 10, 11, 12, 13). B7-H1 is expressed under the control of IFN-
(14) and IFN-β (12). It is found on lymphoid tissues as well as in a variety of nonlymphoid tissues, such as muscle, microvascular endothelial, renal tubular cells, ocular cells, and in cancer cell lines (11, 14, 15, 16, 17, 18, 19, 20). In the inflamed NS, microglia and macrophages were identified as the main sources of B7-H1 expression (11, 21).
Ectopic expression of immune inhibitory B7-H1 by tumors serves as a mechanism for immune evasion (18, 22). Viruses that specifically induce expression of B7-H1 or B7-DC in infected cells may down-regulate the host immune response and favor infectiveness (19, 23). Blockade of the PD-1 pathway may augment antimicrobial immunity and diminish persistent infection in mice. This may lead to new ways of treating chronic viral infections in humans (8, 24). Manipulation of the B7-H1/PD-1 pathway alters the course and severity of autoimmune NS inflammation in animal models of experimental allergic encephalomyelitis (21, 25, 26).
Although B7-H1 is virtually absent from the noninfected NS (4, 7), we wondered whether modulation of B7-H1 could be used by RABV to escape adverse host immune responses. We, therefore, investigated 1) whether B7-H1 was modulated in the NS of mice infected with RABV, 2) whether RABV-infected neurons express B7-H1, and 3) by using B7-H1–/– mice, whether the B7-H1 pathway contributes to RABV neuroinvasiveness.
| Materials and Methods |
|---|
|
|
|---|
Biotinylated anti-mouse B7-H1 (clone MIH5) and biotinylated anti-human B7-H1 (clone MIH1) were from eBioscience. Anti-human B7-H1 NH2 terminus (H-130) Ab was from Santa Cruz Biotechnology. MAP 2 a/b specific Ab was purchased from Abcam. FITC-conjugated rabbit anti-RABV nucleocapsid Ab was from Bio-Rad. Alexa Fluor594-conjugated streptavidin was purchased from Molecular Probes. Cy5-conjugated donkey anti-rat IgG was from Jackson ImmunoResearch Laboratory. Fluoromount-G was obtained from Southern Biotechnology Associates. Fc-Block (anti Fc
III/II receptor rat mAb), anti-mouse CD3, CD19, CD8, and CD4 Abs were from BD Biosciences. Hot Start Taq polymerase and RNeasy Protect kit and Lipid Tissue Midi kit were purchased from Qiagen. Superscript II RT was from InVitroGene. RNA Nano chips were obtained from Agilent. Recombinant human IFN-β was from Schering, rTNF-
from Pharmingen, and rIFN-
from R&D Systems. Percoll was from Amersham Biosciences. OCT compound was from Miles.
Virus, human neural cells, and mice
The laboratory RABV strain CVS (ATCC vr959), a highly pathogenic RABV strain (27) causing fatal encephalomyelitis in mice, was propagated as described (28). HSV-1 strain KOS (29) was propagated on U373MG. B7-H1–/– and TLR3–/– mice were generated as described (30, 31). Six-week-old C57BL6 from Janvier, B7-H1–/–, or TLR-3–/– female mice were inoculated i.m. in both hind legs, with 1 x 107 infectious particles of RABV. Disease progression was evaluated as described by scoring clinical signs and mortality (6). Mobility and mortality were scored as follows: 0 = normal mice, 1 = ruffled fur, 2 = one paralyzed hind leg, 3 = two paralyzed hind legs, 4 = total paralysis (defined as the total loss of mobility), and 5 = death. Daily clinical score was obtained by adding individual scores. Dead mice were reported in the clinical score of the day of the death and thereafter (cumulative scores). Disease progression was presented by a curve of cumulative clinical scores. At days 5, 7, and 9 after infection, groups of two or three mice were perfused. Spinal cords and brains were removed separately and stored at –80°C before being processed for RNA extraction, immunohistochemistry, or mononuclear cell isolation by percol gradient. Animal housing and experimental protocols followed guidelines approved by French Ministry of Agriculture and Ethical committee.
Human NT2-N neurons (32) and mixed cultures neurons/astrocytes, NT2-N/A (33) were differentiated from Ntera-2clD/1 cells as described (34, 35). Purity of the NT2-N and mixed composition of NT2-N/A were checked by RT-PCR as described (36). Human neuroblastoma SK-N-SH cell lines (ATCC; HTB, cat N°11), SK-N-SH-CP, a natural mutant of SK-N-SH disabled for expression of IFN-β, NT2-N, and NT2-N/A cultures were infected with RABV or HSV-1 (7, 36) or treated for 24 and 48 h with IFN-β (1000 U), IFN-
(500 U), or TNF-
(1.25 ng) when needed. Infection was detected by RT-PCR using primers directed against the HSV-1 UL54 gene or the RABV N gene amplicons and by immunocytochemistry as described (37).
Cell cultures from mouse hippocampi prepared from embryos (C57BL/6 mice) at stage E 18, as previously described (11), were incubated with cytokines (IFN-
and-β 500 U/ml and 1000 U/ml, respectively) for 48 h.
Standard and real time RT-PCR
Total RNA was extracted with RNeasy kit (for cells) 24 h after infection or cytokine treatment, or with Lipid Tissue Midikit (for nervous tissues). RNA quality was monitored using Agilent RNA chips. cDNA synthesis was performed with oligo(dT) primers (Table I). Real-time PCR was performed as described (11). Values were expressed as relative increase compared with normalized noninfected or nontreated control (value set to 1) according to the manufacturer's instructions.
|
Dissected brains and spinal cords were snap frozen and embedded in Tissue-Tek OCT. Cryostat sections (8 µm) were fixed in 4% paraformaldehyde, permeabilized in saline phosphate buffer (SPB)- 0.5% Triton X-100, incubated with blocking buffer (5% goat serum and 2% BSA in SPB) and treated 1 h at room temperature (Rt) with biotinylated anti-B7-H1 mouse mAb, then by Alexa Fluor 594-conjugated streptavidin for 30 min at Rt as well as with a rabbit polyclonal FITC-conjugated Ab directed against RABV nucleocapsid.
Immunochemistry on hippocampus cultures was performed on 7-day cultured cells fixed in 20% paraformaldehyde and blocked with 10 mM SPB, 10% horse serum, and 0.2% Triton X-100. Slides were incubated 1 h at Rt with rat anti-mouse B7-H1 and anti-MAP2 mouse Ab then with Cy5-conjugated donkey anti-rat IgG and Cy-2-conjugated donkey anti-mouse finally with 4',6-diamidino-2-phenylindole. Coverslips were mounted in Fluoromount-G and the samples observed under a Leica DM 5000B UV. Images were processed with the Leica FW 4000 software.
Cytofluorimetry for B7-H1 surface expression
Surface expression of B7-H1 was analyzed by flow cytometry. Gently scraped off infected and noninfected SK-N-SH were incubated with biotinylated B7-H1 specific mAb (clone MIH1, 2 µg/106 cells) and then with FITC-conjugated streptavidin. Cells were analyzed by flow cytometry, using a BD Biosciences FACSCalibur equipped with Cell Quest Pro software. Specific fluorescence indices greater than 1.25 were considered positive.
Phenotyping of splenocytes and mononuclear cells infiltrating the NS
CNS mononuclear cells were collected from homogenates of brain and spinal cord samples onto percoll gradients as described (37). Splenocytes or mononuclear cells infiltrating the NS (105 in 50 µl) were assessed by flow cytometry using predetermined optimal concentrations of fluorescent pairs of mAb (CD3/CD19, CD4/CD3, and CD8/CD3). Data analysis was performed with Cell Quest Pro Software.
Measurement of T cells apoptosis in brain infiltrating T cells
Morphological changes to identify cell in intermediate/late stages of apoptosis were assayed by side and forward light scattering flow cytometry analysis as previously described for T cells (38, 39).
| Results |
|---|
|
|
|---|
Previous transcriptome analysis of RABV-infected human neurons NT2-N has allowed us to identify the coinhibitor B7-H1 as a putative target of RABV to escape the host immune response. Further analysis of the neuronal expression of B7-H1 upon RABV infection was pursued in cell cultures of human NT2-N and in a human neuroblastoma cell line (SK-N-SH). NT2-N cell cultures are nearly pure populations of terminally differentiated postmitotic cells. They display biochemical, morphological, and functional characteristics of human neurons (40, 41). Control experiments were performed on the same cells infected with HSV-1. Kinetics of B7-H1 transcription in NT2-N after 1, 6, and 24 h post RABV infection were followed by real time PCR and compared with noninfected conditions (Fig. 1A). The yield of B7-H1 mRNA transcription (black histogram) became detectable after 6 h of RABV infection and markedly increased as infection progressed (gray histograms). B7-H1 molecules could also be detected by cytofluorimetry on the surface of RABV-infected SK-N-SH neuroblastoma after 24 h of infection (Fig. 1B). This evidence was obtained with two distinct B7-H1 Ab from two different sources. This means B7-H1 molecules have reached a location where they could potentially interact with their receptors. As a control experiment, NT2-N cells were infected with HSV-1 under the same experimental protocol as above. Despite a strong infection, as evidenced by RT-PCR (Fig. 1A, right panel) and immunocytochemistry (data not shown), no significant increase of B7-H1 mRNAs could be observed (Fig. 1A; HSV-1 24h). B7-H1 up-regulation in human neurons seems, therefore, specific of RABV infection.
|
The neuronal expression of other members of the B7-family could be affected by RABV infection. We compared the expression level of B7-DC (PD-L2), B7.1 (CD80), and B7.2 (CD86) mRNA after RABV infection in NT2-N and in noninfected cells (Fig. 1C). RABV led to a modest increase of B7-DC (2-fold; black histogram) compared with noninfected cells (white histogram), whereas CD80 and CD86 transcripts were virtually unmodified because the level of transcription was similar to those of CD200R used as negative controls. In addition, the putative contribution of astrocytes to B7-H1 expression in the NS was analyzed in mixed cultures of human neurons and astrocytes (NT2-N/A). The mixed culture mimics the physiological conditions of NS infection by this virus in vivo, as RABV primarily infects neurons and not astrocytes (7, 42). As observed in NT2-N, RABV infection induced up-regulated mRNA expression of B7-H1 and B7-DC transcripts in NT2-N/A in a similar manner as those observed in NT2-N (data not shown), suggesting that neurons mainly contribute to B7-H1 mRNA expression. Neither B7-DC nor B7-H1 transcription was up-regulated in NT2-N or NT2-N/A after HSV-1 infection (Fig. 1C, gray histograms) indicating that up-regulation of B7-H1 and B7-DC—the two ligands of PD-1—is RABV specific.
In the absence of infection, IFN-β or -
trigger B7-H1 expression in human and mouse neural cell cultures
During the course of infection of NT2-N cultures by RABV, expression of B7-H1 mRNA appeared to correlate well with the development of the viral load (compare the two histograms in Fig. 1A). IFN-β mRNA monitored under the same conditions of infection followed a different time course. IFN-β transcription presented a 16-fold increase as early as 1 h post infection and peaked at 6 h post infection (3 x 104 increase; data not shown). It clearly preceded the induction of B7-H1 mRNA synthesis. In contrast, HSV-1 infection did not trigger B7-H1 expression and did not induce IFN-β expression either (data not shown and Ref. 36). IFN-β might, therefore, be required for the induction of B7-H1 expression. We, therefore, analyzed whether the addition of IFN-β to noninfected human NT2-N and NT2-N/A triggers B7-H1 expression. Addition of IFN-
and TNF-
was tested in parallel. IFN-β treatment (24 h, 1000U) led to a significant up-regulation of B7-H1 transcription in NT2-N (appr.50-fold; data not shown) and in NT2-N/A (150-fold; Fig. 1D, black histogram), therefore, indicating that exogenous IFN-β can trigger B7-H1 expression in human neurons and cocultures of neurons and astrocytes. Addition of IFN-
also caused an 80-fold increase of the expression of B7-H1 transcripts in NT2-N/A, whereas TNF-
has a limited effect (Fig. 1D). Of note, B7-DC transcription was only triggered to very limited amounts by IFN-
, -β, and TNF-
in human neurons/astrocytes cultures (Fig. 1D, gray histogram).
Notably, B7-H1 protein expression was also up-regulated in cultures of mouse hippocampus neurons exposed to IFN-
or -β for 48 h (Fig. 2).
|
To test whether in the absence of IFN-β, RABV can still up-regulate B7-H1 expression, we used a human neuroblastoma cell line naturally disabled in the IFN expression (SK-N-SH-CP). We observed in these cells that in absence of IFN-β signaling, RABV cannot up-regulate B7-H1 expression anymore (Fig. 1E), supporting strongly the role of IFN-β in the control of B7-H1.
Expression and regulation of B7-H1 in the mouse NS after RABV infection
First, we monitored the expression and regulation of B7-H1 during NS infection by RABV by assessing brain and spinal cord specimens from animals at an early (day 5) and a late stage of infection (day 7) using real time RT-PCR as well as immunohistochemistry. As expected (11), B7-H1 mRNAs were virtually undetectable in the noninfected NS. In contrast, B7-H1 mRNA expression progressively increased during the course of infection and correlated with the invasion of spinal cord and brain by the virus (Fig. 3A). To identify the cellular source of B7-H1, we performed double immuno-staining analysis detecting infected neurons (in green) and B7-H1 (in red) in brain specimens at days 5 and 7. As shown in Fig. 3, B (x and y-axis) and C (x and y-axis and orthogonal analyses), infected neurons can express B7-H1 (upper panel). This expression occurs primarily in the cellular bodies of RABV-infected neurons and not in the neurites (lower panel of Fig. 3B). The vast majority of infected neurons (70%) can express B7-H1. B7-H1 was also expressed by noninfected cells (data not shown), which correspond to endothelial cells, GFAP+ astrocytes, CD11b+ monocyte/macrophages, and migratory CD3+ T cells (11, 21). The B7-H1 positive CD3+ T cells appeared only at late stages of infection (day 7).
|
is a key cytokine contributing to B7-H1 up-regulation in RABV-infected NS
After having demonstrated the expression of B7-H1 after RABV infection in neuronal cells in vivo and in vitro, we next questioned which cytokines or cytokine-inducing pathways were involved in this in vivo up-regulation. Experiments in wild-type (WT) mice showed that IFN-β and -
expression in the CNS of infected mice (Fig. 4A) was concomitant with an increase of B7-H1 expression (see Fig. 3A). To further analyze the role of IFN-β in the up-regulation of B7-H1 after RABV-infection, we investigated mice with impaired IFN-β production. As a model, we initially used mice lacking receptor for IFN
/β (IFN-R
/β–/– mice). However, in these mice, rabies is fulminant. All mice were dead 4 days after infection, a period too short to study B7-H1 up-regulation in the brain (data not shown). We turned to TLR3–/– mice (31) because we noticed that upon RABV infection, IFN-β expression was significantly decreased in TLR3–/–mice brains compared with WT mice. TLR3–/– and WT mice were infected with RABV and sacrificed 5 and 7 days after infection. Transcripts of IFN-β, -
, and B7-H1 were quantified in the brain by real-time PCR (Fig. 4B). We found that B7-H1 up-regulation at day 7 was significantly decreased in TLR3–/– mice brains in comparison to WT (152-fold increase in WT and 56-fold increase in TLR3–/– brains). This was concomitant with a limited up-regulation of IFN-β mRNA as compared with WT (516-fold increase in WT compared with 113-fold increase in TLR3 –/– mice). In contrast, IFN-
up-regulation was not reduced but showed a significant increase (7-fold increase compared with IFN-
transcription in WT brains). However, despite the high expression of IFN-
transcripts in TLR3–/– mice, B7-H1 expression was diminished. These observations support the hypothesis that IFN-β–and not IFN-
–is a key contributor to the up-regulation of B7-H1 expression in the NS upon RABV infection.
|
We found that RABV specifically triggers the regulation and the surface expression of B7-H1 in infected neurons. Various reports have demonstrated that B7-H1 provides an inhibitory signal in the interaction with Ag-specific T cells. Importantly, B7-H1 is responsible for the exhaustion of antiviral T cell responses by triggering the anergy of activated T cells (19). We, therefore, tested whether this key molecule was involved in the immunoevasive strategy of RABV. To do so, we compared the progression and the outcome of RABV infection in mice lacking B7-H1 (30) with WT mice. B7-H1–/– mice and control WT C57BL6 mice (n = 8 in each group) were injected with a dose of virus expected to kill half of the mice (ED50). Mice were observed during 16 days post infection. Progression of the disease in the two groups of mice is illustrated by the cumulative clinical curves. Clinical signs (Fig. 5A) as well as mortality records (Fig. 5B) were assessed. In both groups, half of the mice started losing weight 6 days after infection (data not shown), indicating that they were infected. Consistent with our expectation for this injected dose, in both groups, half of the mice showed clinical signs of disease, including loss of hindlimbs mobility. However, in striking contrast to disease course observed in WT animals, clinical signs of encephalitis, such as hunchback, did not occur in sick B7-H1–/– mice. Mean cumulative clinical score was significantly decreased in B7-H1–/– mice compared with WT mice (Fig. 5A). By day 9, consistent with the dose of virus injected (dose 50), half of the WT mice died, whereas B7-H1 mice survived (Fig. 5B). Infection of mice with a dose that killed 100% of WT mice (dose 100) only killed half of the B7-H1 mice (Fig. 5B). Neuroinvasiveness was compared in those mice, by measuring the amount of transcripts of viral N protein in the brain stem of RABV-infected WT and B7-H1–/– mice at days 5 and 10. A reference value of 1, taken for noninfected NS, was used for calibration. As shown in Fig. 5C, the viral transcription was drastically reduced in B7-H1–/– NS (38-fold less) as early as day 5 (83 value for N mRNAs in B7-H1–/– and 3.200 in WT NS samples). The difference was more pronounced at day 10 post infection, with 690-fold less viral transcription in the brain stem of B7-H1–/– mice than in WT (460-fold increase of N mRNAs for B7-H1–/– and 320,000-fold increase in WT mice). RABV neuroinvasiveness was, therefore, severely impaired in the absence of B7-H1.
|
CD8+ T cell infiltration into the RABV-infected NS is maintained in the absence of B7-H1
We previously observed that the severity of RABV infection was inversely correlated with the number of CD3+ and CD8+ T cells in the NS (6, 37). Conclusions of these previous studies were that highly neuroinvasive and pathogenic infections were associated with a severe drop in the number of CD3+ T cells of migratory cells into the NS, whereas high amounts of CD3+ or CD8+ migratory T cells were observed in poorly neuroinvasive and less pathogenic RABV infection.
The effect of RABV infection on the subpopulations of CD3+, CD4+, and CD8+ in the pool of migratory T cells into the NS was further analyzed by cytofluorimetry and compared with those found in the periphery (spleen). WT and B7-H1–/– mice were infected with RABV. Splenocytes and NS immune cells were analyzed by cytofluorimetry 5 and 10 days postinfection in WT and B7-H1–/– mice. Analysis of CD4+ and CD8+ splenocytes indicated that RABV infection does not modify the CD4:CD8 ratio in the spleen during infection of WT and B7-H1–/– mice (Table II).
|
|
| Discussion |
|---|
|
|
|---|
RABV is a pathogen well-adapted to the NS, where it infects neurons. It is transmitted by the bite of an infected animal. It enters the NS via a motor neuron through the neuromuscular junction, or via a sensory nerve through nerve spindles. It then travels from one neuron to the next, along the spinal cord to the brain and the salivary glands. The virions are excreted in the saliva of the animal and can be transmitted to another host by bite (43). Thus, preservation of the neuronal network integrity is crucial for the virus. Successful invasion of the NS by RABV seems to be the result of a subversive strategy based on the survival of infected neurons (5, 44). This strategy includes protection against virus-mediated apoptosis and destruction of T and NK cells that invade the NS by redundant control of the expression of the immunosubversive molecules FasL and HLA-G (4, 6, 44). The present study strongly suggests that this strategy also includes CD8+ T cell exhaustion/death by the B7-H1/PD-1 pathway. CNS-derived B7-H1 might be operative in inhibiting local T cell expansion or even directly "eliminate" T cells, e.g., by apoptosis (6) as demonstrated in other systems, such as cornea (20). Previous studies indicated that T cells entering the NS underwent apoptosis in the course of RABV infection in mice (5, 6). We observed that in WT mice, the CD8+ T cells entering the NS encounter apoptosis (Fig. 6E); this number was reduced by 50% in the B7-H1–/– mice, indicating that B7-H1 contributes to the apoptosis of effector T cells infiltrating the infected NS. B7-H1-mediated killing of CD8+ T cells was obtained in cocultures of MHC and B7-H1 expressing neurons with activated OT-1 CD8+ T cells (S. Meuth, O. Simon, and H. Wiendl, manuscript in preparation). The fact that reduction of CD8+ T cell apoptosis was not completely abrogated in RABV-infected B7-H1–/– mice may suggest that other proapoptotic factors were still expressed by B7-H1–/–-infected neurons. The remaining CD8+ T cells death could be the result of the expression of B7-DC the second receptor for PD-1, which expression was increased in neuronal cultures by RABV infection (Fig. 1D). Because B7-H1 is expressed by inflammatory cells (Ref. 11 and this manuscript), killing of CD8+ T cells may also be a result of B7-H1-positive microglia and macrophages. Killing of CD8+ T cells would, thus, be expected to occur in any NS infection in which IFN is produced, microglia is activated, and macrophages infiltrate the NS. However, in such an infection model (West Nile infection), we did not observed any decrease in the number of migratory T cells (45). Thus, it is unlikely that B7-H1 expressed by inflammatory cells is a major pathway to promote migratory T cell death in the infected NS.
Our findings are in good accordance with recent observations demonstrating that absence of B7-H1 leads to a more efficient elimination of adenovirus in mice (46) and that in human rhinovirus infection, the B7-H1/PD-1 pathway triggers a hindered immune response in the respiratory tract (23). They are also reminiscent of what has been observed in Schistosomia where infected macrophages up-regulate B7-H1 molecules thereby exhausting the host immune response (47). Very recently, PD-1 on T cells has been attributed to an exhausted phenotype of Ag-specific CD8 T cells, a phenomenon relevant in chronic infections with immuno-evasive viruses, such as chronic lymphocytic choriomeningitis virus, (19), HIV (48, 49), and hepatitis C virus (50, 51). But, our results also stress a specific and important aspect of RABV infection, its "organ-specificity". In this study, the B7-H1/PD1 pathway is specifically manipulated upon infection in the NS. Expression of B7-H1 is modulated in this organ as well as B7-H1-induced changes in CD4:CD8 ratio in the NS. This takes place despite the fact that no change in the CD4:CD8 ratio occurred in the periphery and despite the fact that WT mice as well as B7-H1–/– mice develop similar RABV-specific serum Abs (data not shown), strongly suggesting that mounting of primary immune response against RABV was not altered by the absence of B7-H1. We can conclude that it is the specific B7-H1 overexpression in the RABV-infected NS that contributes to the immunoevasiveness of the virus. However, among neuronotropic viruses, up-regulation of B7-H1 could not be shared by every virus because, as reported here, HSV-1 did not alter B7-H1 expression and only partially counteracts and escapes the host immune responses (7).
We observed that mice lacking TLR3 showed a reduced B7-H1 expression, suggesting that TLR3 signaling was involved in B7-H1 regulation. Because TLR3–/– mice develop a less severe form of RABV it can be hypothesized that TLR3 signaling pathway facilitates the immunoevasion. If this is the case, it will be reminiscent of the finding that in tumor cells, TLR4 signaling enhances immune suppression in vitro and that converse blockade of TLR4 prolongs the survival of mice grafted with tumor (52). Involvement of TLR signaling in induced B7-H1 expression has been observed in tumor cells where ligation of TLR2, 4, and 9 with agonists (peptidoglycan, LPS, and double strand decoy oligodeoxynucleotides, respectively) induced B7-H1 expression (52, 53). We recently established that human neurons express TLR3 and can mount a chemoattractive, inflammatory, and antiviral-including IFN-β responses after RABV infection. TLR3 expression was found to be enhanced by RABV infection in human neurons in cultures as well as in autopsied rabies cases (36, 54). Whether TLR3 signaling is also involved in B7-H1 deserves further investigation. Nevertheless, because signalization through TLRs, such as TLR3, leads to the mounting of an IFN response, IFN response may be one arm of the TLR3-mediated regulation of B7-H1.
Both type I and II IFNs (IFN-β and -
) have been described to up-regulate B7-H1 transcripts in human DCs and monocytes (12). IFN regulatory factor 1 (IRF1) is a crucial factor in the IFN-
-induced up-regulation of B7-H1(55). Our results indicate that IFN-β and -
also control B7-H1 expression in human neurons and astrocytes as well as in mouse hippocampal neuronal cultures. In the course of RABV infection, IFN-β production by the infected NS precedes the onset of B7-H1 transcription, which is virtually absent in noninfected NS. Severely impaired IFN-β production (as observed in RABV-infected TLR3–/– mice) is associated with a decrease in B7-H1 transcription. Therefore, B7-H1 up-regulation in the NS occurs as a response to or at least requires the presence of a specific "inflammatory" or cytokine milieu. The fact that HSV-1 does not trigger B7-H1 expression in HSV-1-infected neurons is fully consistent with the contribution that IFN-β exerts in the regulation of B7-H1 transcription, because HSV-1 strictly inhibits host IFN response (36, 56). It is surprising that B7-H1 expression in TLR3–/– brains was still reduced despite the production of large amounts of IFN-
transcripts in these tissues. This may indicate that—at least in vivo–B7-H1 expression requires a production of IFN-β and -
above a certain threshold and/or that synergetic effects between the two cytokines are required.
In any case, these observations suggest that B7-H1 up-regulation in the NS occurs as a response to or in the presence of a specific "inflammatory" cytokine milieu (11). In the instance of autoimmune NS inflammation, expression of B7-H1 is localized within areas of strongest inflammation and is considered to act as a "negative" regulatory feedback loop for keeping the "anti-inflammatory milieu" in the NS (4). Such a tissue tolerance function of B7-H1 has similarly been postulated in other parenchymateous organs, as recently shown for the pancreas in a disease model of autoimmune diabetes (9, 10). Although the inhibitory function of tissue related B7-H1 is beneficial in the instance of (autoimmune) inflammatory aggression, it has opposite effects in the case of viral infection; here, the virus diverts a feed back loop to its own strategy. In the case of RABV, a pathogen well adapted to the NS, we propose that B7-H1 acts as a viral target for immune evasion.
Our data support a sequential scheme of events after NS infection by RABV contributing to RABV immunoevasion. Early in NS infection by RABV, NS cells mount an innate immune response including TLR3 signaling and IFN-β production leading to B7-H1 expression. Infected neurons that express TLR3 can directly contribute to the IFN-β production. B7-H1 protein subsequently reaches the cell surface of the infected neurons, where it could interact with its main receptor, PD-1, known to be expressed by T as well as B cells. Interaction of B7-H1 with PD-1 would then trigger the exhaustion of CD8+ T cells (e.g., reducing cell expansion or promoting active elimination) and, thus, favor the viral invasion of the NS. This pathway appears of crucial importance to ensure the progression of the disease in the NS because mice eliminate much more efficiently the invading virus when it is abrogated.
Taken together, our data provide evidence for an important role of the B7-H1/PD-1 pathway in some neurotropic infections. The demonstration of neuronal expression of B7-H1 after a RABV infection and the fact that mice lacking B7-H1 have a significant survival advantage clearly advocate the notion that B7-H1 is critically involved in the strategies used by RABV to escape the host immune response. Interference affecting the B7-H1/PD-1 interactions might then be envisioned as a possible therapeutic approach to strengthen and expand actual post exposure treatment of human rabies.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by grants from Institut Pasteur including PTR 186 (to M.L.), the Deutsche Forschungsgemeinschaft (SFB581, TPA8 to H.W.), and the Interdisciplinary Center for Clinical research (48-0-0, to H.W.). ![]()
2 Address correspondence and reprint requests to Dr. Monique Lafon, Unité de Neuroimmunologie Virale, Institut Pasteur, 25, rue du Dr. Roux, 75724 Paris Cedex 15, France. E-mail address: mlafon{at}pasteur.fr ![]()
3 Abbreviations used in this paper: RABV, Rabies virus; NS, nervous system; Rt, room terperature; WT, wild type. ![]()
Received for publication August 24, 2007. Accepted for publication March 26, 2008.
| References |
|---|
|
|
|---|
receptor promotes survival in rabies virus acute encephalitis. J. Neurovirol. 6: 507-518. [Medline]
B by Toll-like receptor 3. Nature 413: 732-738. [Medline]
and TLR ligands via a MyD88-. TRAF6-, and MEK-dependent pathway. Blood 110: 296-304.
-induced upregulation of B7-H1 (CD274). FEBS Lett. 580: 755-762. [Medline]This article has been cited by other articles:
![]() |
N. Melzer, S. G. Meuth, and H. Wiendl CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability FASEB J, November 1, 2009; 23(11): 3659 - 3673. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Castel, M. Chteoui, G. Caignard, C. Prehaud, S. Mehouas, E. Real, C. Jallet, Y. Jacob, R. W. H. Ruigrok, and N. Tordo Peptides That Mimic the Amino-Terminal End of the Rabies Virus Phosphoprotein Have Antiviral Activity J. Virol., October 15, 2009; 83(20): 10808 - 10820. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Phares, C. Ramakrishna, G. I. Parra, A. Epstein, L. Chen, R. Atkinson, S. A. Stohlman, and C. C. Bergmann Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous Sysyem Infection and Dampens Morbidity J. Immunol., May 1, 2009; 182(9): 5430 - 5438. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |